A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. Researchers described the case in a new study, ...
Add Yahoo as a preferred source to see more of our stories on Google. Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The ...
Jacksonville may host one of the first U.S. gene‑editing trials aimed at permanently lowering LDL in inherited high ...
KJ Muldoon was diagnosed with a rare genetic disorder when he was born called severe CPS1 deficiency. KJ is one in a million babies that are diagnosed with this illness. Researchers and doctors used ...
When applied to human eggs, sperm and embryos, gene-editing technologies, of which CRISPR is the most precise, can alter the ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...
Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term growth.
Zheng-Yi Chen, DPhil, associate scientist at the Eaton-Peabody Laboratories, and Ines and Fredrick Yeatts Chair in Otolaryngology, at Mass Eye and Ear, is the senior and co-corresponding author of a ...
Biotech companies that use gene editing tools can face intellectual property (IP) challenges during commercialization. That’s the view of Austin Hallgren, strategic account manager for bioproduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results